Roivant Sciences Ltd. (ROIV)
Automate Your Wheel Strategy on ROIV
With Tiblio's Option Bot, you can configure your own wheel strategy including ROIV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ROIV
- Rev/Share 0.135
- Book/Share 7.66
- PB 1.5612
- Debt/Equity 0.0193
- CurrentRatio 37.9122
- ROIC -0.1742
- MktCap 7620625260.0
- FreeCF/Share -1.0785
- PFCF -9.7766
- PE -69.4699
- Debt/Assets 0.0173
- DivYield 0
- ROE -0.021
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q4 2024 Earnings Conference Call May 29, 2025 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Richard Pulik - Chief Financial Officer Conference Call Participants Brian Cheng - JPMorgan Chase & Co. David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Samuel Slutsky - LifeSci Capital Yatin Suneja - Guggenheim Securities Douglas Tsao - H.C.
Read More
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Negative
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.16.
Read More
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of Immunovant Pete Salzmann, M.D.
Read More
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two new indications, SjD and CLE.
Read More
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Published: March 19, 2025 by: Investors Business Daily
Sentiment: Positive
Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.
Read More
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.
Read More
All You Need to Know About Montes Archimedes Acquisition (ROIV) Rating Upgrade to Buy
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of calendar year with topline data in second half of calendar year 2026 IMVT-1402 development is rapidly progressing with six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) initiated Batoclimab …
Read More
About Roivant Sciences Ltd. (ROIV)
- IPO Date 2020-12-08
- Website https://roivant.com
- Industry Biotechnology
- CEO Mr. Matthew Gline
- Employees 908